Register of Members' Interests: Scientific Advisory Committee on Genetic Modification

Members have declared the following commercial and non-commercial interests deemed relevant to their appointment to the SACGM. N.B. share holdings need only be declared if they exceed £25,000.

Prof Janet Bainbridge (Chair)

Employer: Self-employed consultant
Commercial Interests: None
Non-commercial Interests: None

Dr Gary Burns

Employer: AstraZeneca
Commercial Interests: Company shares
Non-commercial Interests: None

Dr John Carr

Employer: Cambridge University
Commercial Interests: None
Non-commercial Interests: Research grants received from various sources including BBSRC, Leverhulme Trust, Royal Society, DEFRA.

Dr Martin Carrier

Employer: Queen Mary, University London
Commercial Interests: None
Non-commercial Interests: None

Dr Peter Coyle

Employer: Royal Group of Hospital Trust, Belfast
Commercial Interests: None
Non-commercial Interests: None

Prof Martin Gore (Vice Chair)

Employer: Royal Marsden Hospital
Commercial Interests: None Non-commercial Interests: Medical Director: Rare Cancers Division. Head of Melanoma Unit. Vice-Chair of the Gene Therapy Advisory Committee. Co-chair of the sub-committee on retroviral safety and the gene therapy working party. Member of the editorial board of a number of scientific journals.

Prof Ernest Gould

Employer: NERC
Commercial Interests: None
Non-commercial Interests: Holder and collaborator in research funding from BBSRC, Wellcome Trust, DSTL and several small drug companies.

Dr Penny Hirsch

Employer: Rothamstead Research
Commercial Interests: None
Non-commercial Interests: BBSRC - CASE studentship; industrial sponsor, Syngenta, 2001-4 (Syngenta give some support to the student, none to Rothamstead or Dr Hirsch).

Dr Keith Howard

Employer: Baxter Vaccines AG
Commercial Interests: None
Non-commercial Interests: None

Dr David Lewis

Employer: St George's Hospital Medical School
Commercial Interests: None
Non-commercial Interests: Most current research funded by European Commission 6th Framework: one grant to test vaccines/antibodies from transgenic plants (approx £410k), second to develop live mucosal vaccines (approx £750k). One current grant involving GMOs funded by Institute Pasteur Paris (£120k); two previously from Microscience (approx £335k); and one each from Wellcome Trust, MRC and WHO (approx £470k total). Occasional adviser to FAP (Brazilian League Against Tuberculosis) on recombinant BCG.

Dr Philip Minor

Employer: NBSB
Commercial Interests: None
Non-commercial Interests: None

Mr Robert Osborne

Employer: University of Glasgow
Commercial Interests: None
Non-commercial Interests: None

Dr Brian D Robertson

Employer: Imperial College, London
Commercial Interests: None
Non-commercial Interests: None

Dr Peter Searle

Employer: University of Birmingham
Commercial Interests: None
Non-commercial Interests: Biological Safety Officer at the Institute for Cancer Studies, and the University Hospital Birmingham NHS Trust. Collaborative relationship (unpaid) with ML Laboratories, which has involved funding a research project in my laboratory. Research funding currently from MRC.

Dr Michael Skinner

Employer: Imperial College, London
Commercial Interests: I am a co-inventor on patents relating to genetically modified vaccines for poliovirus and for a fowlpox virus recombinant vaccine vector. The latter is being actively pursued and has been commercially licensed by Oxxon Therapeutics (for whom I have acted as a consultant on technical matters of recombinant virus isolation and propagation). I have received patent income via the BBSRC's 'rewards for inventors' scheme.
Non-commercial Interests: Research in my lab is currently funded by the BBSRC, with MRC and Wellcome Trust as likely funders following a recent move to Imperial College. Until December 2005, a project on recombinant fowlpox vectors will be funded by Oxxon Therapeutics (c. £75k pa). I have acted as a WHO special adviser on recombinant vaccines. I act as external PhD examiner to various universities.